Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: VistaGen Therapeutics Inc. VTGN

VistaGen Therapeutics’ (NASDAQ: VTGN) New Generation Phase 3 Drug Candidate for Social Anxiety Disorder Gains Importance Amid FDA Wariness of Benzodiazepines

Posted on November 5, 2020 by MissionIR

VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disorders PH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorder Company sees … Continue reading →

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Stock2Me Podcast

Posted on November 3, 2020 by MissionIR

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via … Continue reading →

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder

Posted on November 2, 2020 by MissionIR

Study results have exciting therapeutic potential across wide range of CNS indications. VTGN focused on developing new generation of medications to treat anxiety, depression and more. Company committed to finding treatment to help estimated 264 million people around the world … Continue reading →

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article

Posted on October 30, 2020 by MissionIR

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” … Continue reading →

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report

Posted on October 8, 2020 by MissionIR

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report reads, “VistaGen is developing multiple … Continue reading →

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’

Posted on October 7, 2020 by MissionIR

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Based out of South San … Continue reading →

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is “One to Watch”

Posted on October 2, 2020 by MissionIR

VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety … Continue reading →

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment

Posted on October 1, 2020 by MissionIR

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated over 25 years to biopharma … Continue reading →

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety

Posted on September 30, 2020 by MissionIR

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, … Continue reading →

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials Publication

Posted on September 29, 2020 by MissionIR

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was recently featured in an Applied Clinical Trials article titled, “Pushing Late-Stage Treatments Forward in the Clinic.” In the … Continue reading →

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment